Publications by authors named "J M Casasnovas"
Virus-Receptor Interactions and Receptor-Mediated Virus Entry into Host Cells.
Subcell Biochem
December 2024
The virus particles described in the previous chapters of this book are vehicles that transmit the viral genome and the infection from cell to cell. To initiate the infective cycle, the viral genome must therefore translocate from the viral particle to the cell cytoplasm. Via distinct proteins or motifs in their outermost shell, the particles of animal viruses or bacteriophages attach initially to specific receptors on the host cell surface.
View Article and Find Full Text PDF: The hepatitis A virus (HAV) cellular receptor 1 (HAVCR1) is a type I integral membrane glycoprotein discovered in monkeys and humans as a HAV receptor. HAVCR1 contains an N-terminal immunoglobulin-like variable domain (IgV) followed by a mucin-like domain (Muc), a transmembrane domain, and a cytoplasmic tail with a canonical tyrosine kinase phosphorylation site. The IgV binds phosphatidylserine on apoptotic cells, extracellular vesicles, and enveloped viruses.
View Article and Find Full Text PDFPhysical activity (PA) intensity could play a key role in atherosclerosis risk, but the existing literature shows controversial results. The aim of this study was to analyze the association of different PA levels with the presence of subclinical atherosclerosis in femoral and carotid arteries. A cross-sectional analysis was conducted of 449 middle-aged men belonging to the Aragon Workers' Health Study.
View Article and Find Full Text PDFMVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
Front Immunol
September 2024
Article Synopsis
- - The Omicron subvariants of SARS-CoV-2 are highly infectious and can evade immunity provided by initial COVID-19 vaccines, prompting interest in developing new vaccines tailored to these variants.
- - A new vaccine candidate, MVA-S(3P_BA.1), was created using a modified vaccine virus to express the spike protein from the Omicron BA.1 variant, and its effectiveness was tested in comparison to existing vaccine candidates.
- - All tested vaccines protected mice against the Omicron variant, lowering viral loads and inflammatory responses, with the new MVA-S(3P_BA.1) vaccine and a bivalent vaccine showing superior antibody production and a broader immune response to multiple variants.
Article Synopsis
- Current SARS-CoV-2 mRNA vaccines are effective, but there's a need for new strategies due to waning immunity and variant emergence, prompting this study on a heterologous mRNA/MVA vaccination approach.
- The research demonstrates that a combination of a trimeric receptor binding domain (RBD) delivered via mRNA and a modified vaccinia virus (MVA) boost creates strong immune responses, including effective antibodies and T cell activity against various SARS-CoV-2 strains.
- The heterologous regimen provided complete protection in specific mouse models after exposure to the virus, outperforming traditional methods and suggesting that alternative nanocarrier technologies could enhance vaccine effectiveness while avoiding patent issues.